United Therapeutics Corporation Stock

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-21 EDT 5-day change 1st Jan Change
275.2 USD +0.19% Intraday chart for United Therapeutics Corporation +2.01% +25.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.73B 3.73B Sales 2025 * 2.95B 4.03B Capitalization 12.19B 16.64B
Net income 2024 * 1.18B 1.62B Net income 2025 * 1.29B 1.76B EV / Sales 2024 * 3.66 x
Net cash position 2024 * 2.19B 2.99B Net cash position 2025 * 3.95B 5.39B EV / Sales 2025 * 2.79 x
P/E ratio 2024 *
11.2 x
P/E ratio 2025 *
10.3 x
Employees 1,168
Yield 2024 *
-
Yield 2025 *
-
Free-Float 58.63%
More Fundamentals * Assessed data
Dynamic Chart
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024. CI
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
1 day+0.19%
1 week+2.01%
Current month+17.44%
1 month+17.57%
3 months+25.55%
6 months+19.42%
Current year+25.15%
More quotes
1 week
269.93
Extreme 269.93
279.98
1 month
233.28
Extreme 233.275
279.98
Current year
208.62
Extreme 208.6249
279.98
1 year
204.44
Extreme 204.44
279.98
3 years
158.38
Extreme 158.38
283.09
5 years
74.31
Extreme 74.31
283.09
10 years
74.31
Extreme 74.31
283.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 96-06-25
President 52 11-03-31
Director of Finance/CFO 56 12-12-31
Members of the board TitleAgeSince
Director/Board Member 76 01-12-31
Chief Executive Officer 69 96-06-25
Director/Board Member 81 09-12-31
More insiders
Date Price Change Volume
24-05-21 275.2 +0.19% 317 142
24-05-20 274.7 +0.15% 333,292
24-05-17 274.3 +0.75% 329,299
24-05-16 272.2 -0.17% 463,903
24-05-15 272.7 +1.08% 370,399

Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm

More quotes
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
274.7 USD
Average target price
294.2 USD
Spread / Average Target
+7.10%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW